Young Breast Cancer Survivors Without a Germline Pathogenic Variant Have a Low Risk of Developing a Second Primary Breast Cancer In the First 10 Years After Diagnosis
Findings from the Young Women’s Breast Cancer Study
Digital Health as Cancer Care Facilitator: the Power of a Standardised European Health Record 2024
23 Apr 2024
Chairs: Anna Pellat, Carola Schulz
Speakers: Maria Alice Borinelli-Franzoi, Daniëlle Seinstra, Henrique Martins
Programme
The MAP 2024 programme is now online!
Patient Guide in Stomach Cancer Now Available in Hungarian
ESMO would like to thank the Gyógyulj Velünk Egyesület (GYVE) for providing translation in the Hungarian language
Efficacy and Safety of FOLFIRI With Durvalumab With or Without Tremelimumab as the Second-Line Treatment in Patients With Advanced Gastric/GEJ Adenocarcinoma
Findings from the PRODIGE 59-FFCD 1707-DURIGAST study